Entero Therapeutics, Inc. (ENTO)
NASDAQ: ENTO · Real-Time Price · USD
2.275
+0.125 (5.81%)
Aug 29, 2025, 4:00 PM - Market closed

Company Description

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.

It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI.

The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.

Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Entero Therapeutics, Inc.
Entero Therapeutics logo
CountryUnited States
Founded2014
IPO DateOct 11, 2016
IndustryBiotechnology
SectorHealthcare
Employees2
CEORichard Paolone

Contact Details

Address:
777 Yamato Road, Suite 502
Boca Raton, Florida 33431
United States
Phone561 589 7020
Websiteenterothera.com

Stock Details

Ticker SymbolENTO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001604191
CUSIP Number33749P507
ISIN NumberUS33749P5070
Employer ID46-4993860
SIC Code2834

Key Executives

NamePosition
Richard Joel PaoloneChief Executive Officer and Director
Anna SkowronChief Financial Officer

Latest SEC Filings

DateTypeTitle
Aug 26, 2025S-1General form for registration of securities under the Securities Act of 1933
Aug 26, 2025PRE 14AOther preliminary proxy statements
Aug 18, 2025DNotice of Exempt Offering of Securities
Aug 15, 20258-KCurrent Report
Aug 14, 202510-QQuarterly Report
Aug 11, 20258-KCurrent Report
Jul 16, 20258-KCurrent Report
Jul 8, 20258-KCurrent Report
Jul 2, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Jul 2, 20258-KCurrent Report